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The carboxyl terminus of G protein a subunits plays
an important role in receptor recognition. To identify
the amino acids that participate in this interaction,
COOH-terminal mutants of at (the transducin a subunit)
were expressed in vitro and analyzed for their ability to
interact with rhodopsin and to bind guanine nucleotide.
Gly-348, the reported site of a b turn, was replaced with
other neutral amino acids without severely affecting
rhodopsin binding. However, proline substitution abol-
ished rhodopsin interaction, suggesting that flexibility
is important at this site. A comparison between C347Y,
which lost both rhodopsin and guanine nucleotide bind-
ing, and a mutant substituted with aq sequence (D346E/
C347Y/G348N/F350V), in which guanine nucleotide bind-
ing was restored, implies that distinct motifs maintain
the structure of the a subunit and are necessary for
selective interaction with receptors. Surprisingly, mu-
tants L344A, L349A, F350stop, and stop351A demon-
strated a parallel loss of rhodopsin and guanine nucle-
otide binding. Altered profiles of L344A and F350stop on
sucrose density gradients indicate that these mutants
may undergo denaturation. The equivalent of atL344A
generated in as and ai did not show such a severe loss of
guanine nucleotide binding, revealing that the at car-
boxyl terminus is unique in its susceptibility to changes
in amino acid sequence.
Transducin (Gt),
1 a heterotrimeric G protein activated by
rhodopsin in response to light, regulates visual signal trans-
duction pathways in the vertebrate rod cell. Because of their
relative abundance, the Gt a, b, and g subunits and rhodopsin
have been used extensively as structural models for the study
of receptor-G protein interaction. Several investigations have
indicated that the COOH terminus of the a subunit plays an
important role in receptor recognition. For example, the inter-
action of at with rhodopsin can be disrupted by ADP-ribosyla-
tion of the COOH-terminal cysteine (Cys-347) with pertussis
toxin (1). A synthetic peptide corresponding to the COOH-
terminal 11 amino acids of the a subunit can also block the
binding of at to rhodopsin. When added alone, this peptide can
stabilize the active form of rhodopsin, metarhodopsin II, a
property of the G protein heterotrimer (2). NMR studies have
demonstrated that this peptide exhibits dramatic conforma-
tional changes when incubated with light-activated rhodopsin,
strongly suggesting that the COOH terminus of at binds to
rhodopsin and undergoes conformational changes necessary for
the promotion of guanine nucleotide exchange (3). A number of
studies (for review, see Ref. 4) have verified the participation of
the a subunit COOH terminus in receptor coupling for other G
proteins (5–12). Despite the extensive literature on this sub-
ject, the mechanism by which these amino acids interact with
G protein-coupled receptors is not well understood, although it
has been proposed that a conserved glycine in the ai/o/t family
plays a central role in regulating the conformation of the
COOH terminus (3, 11).
In this report, we undertake a mutational strategy to define
the COOH-terminal amino acids of at that participate in recep-
tor interaction. Efforts to express the full-length at polypeptide
have so far been unsuccessful using either bacterial or baculo-
virus expression, although recently an amino-terminal trunca-
tion of at has been expressed (13). We have chosen the method
of in vitro translation, which has allowed us to generate full-
length, radiolabeled at for rhodopsin interaction and guanine
nucleotide binding studies. This system has been used success-
fully by several laboratories to investigate both the receptor
and effector coupling properties of as (14, 15) and guanine
nucleotide binding properties of ao (16). Our studies have re-
vealed the selective importance of specific amino acids in the
interaction between the at and rhodopsin. We have also ob-
served that certain mutations in the COOH terminus destroy
both rhodopsin binding and guanine nucleotide binding, per-
haps by significantly altering their tertiary structure. Equiva-
lent mutants in ai and as were not as severely affected, sug-
gesting that the at COOH terminus is unique in its structural
properties compared to other G protein a subunits.
EXPERIMENTAL PROCEDURES
Isolation of Rod Outer Segments—Urea-stripped rod outer segments
(ROS) containing rhodopsin were isolated in the dark from frozen,
dark-adapted retina (W. H. Lawson, Lincoln, NE) on 25/30% (w/w)
sucrose gradients as described (17, 18). The concentration of functional
rhodopsin, quantified by absorbance at 500 nm and using an extinction
coefficient of 42,700 M21 cm21 (19), was 4 mg/ml. The purity was approx-
imately 90%, estimated by Coomassie Blue staining on SDS-polyacryl-
amide gels. ROS membranes were analyzed for the presence of at and
bg by immunoblot analysis (20). The membranes were chromato-
graphed on 10% polyacrylamide gels, transferred to nitrocellulose, and
incubated with AS/7, an anti-COOH-terminal antibody that recognizes
both at and ai (DuPont NEN), and with an antibody that recognizes
Gtbg (a gift from Dr. Gary L. Johnson, National Jewish Center for
Immunology and Respiratory Medicine, Denver, CO). The binding of
the antibodies was visualized by incubation with 125I-protein A and
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autoradiography.
Mutagenesis of at—The EcoRI-PstI fragment from the at cDNA (a gift
from Dr. Henry Bourne, University of California at San Francisco) (21)
was inserted into pSelect (Promega) at the HindIII site by the addition
of HindIII linkers. Site-directed mutagenesis was performed using the
“Altered Sites” mutagenesis system according to the manufacturer’s
protocols (Promega).
Preparation of in Vitro Translated Subunits—The double-stranded
pSelect-at and mutant constructs were linearized with EcoRV and
incubated with T7 polymerase to synthesize sense RNA (22). The RNAs
were incubated at 30 °C for 1 h with rabbit reticulocyte lysate (Pro-
mega) in the presence of 2 ml of [35S]methionine (1200 Ci/mmol; Amer-
sham Life Sciences) in a final volume of 25 ml according to the manu-
facturer’s directions. The radioactivity incorporated into protein was
measured as the insoluble fraction from a hot trichloroacetic acid pre-
cipitation (23). The mutant and wild-type as and ai2 cDNAs (24) were
inserted into the HindIII site of pSP72 (Promega). All procedures for in
vitro transcription and translation were carried out as described for at.
Rhodopsin Binding Assay—The in vitro translation products were
diluted 2-fold and centrifuged through Bio-Spin P-6 columns (Bio-Rad)
to remove salts and free nucleotides. The eluates were equilibrated in
buffer A (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl2, and 1 mM
dithiothreitol). Urea-stripped ROS membranes containing 7 mg (0.18
nmol) of rhodopsin were mixed with approximately 50,000 cpm (0.02
pmol) of in vitro translated mutant or wild-type at in buffer A and
incubated for 30 min at 4 °C. Experiments were performed in the light
or the dark and in the presence or absence of 200 mM GTPgS. To
terminate the assay, the reaction mixtures were centrifuged in a TLA45
rotor (Optima TLX centrifuge, Beckman) at 45,000 rpm through a
cushion of 0.2 M sucrose in buffer A. After rinsing with buffer A, the
pellets were resuspended in SDS-Laemmli sample buffer (25) and chro-
matographed on 10% SDS-polyacrylamide gels. The gels were treated
with Amplify (Amersham) and autoradiographed. The amount of mu-
tant or wild-type at bound to ROS membranes was quantified by phos-
phorimage analysis (Molecular Dynamics). The specific binding of at to
rhodopsin was calculated as the amount bound in the absence of GTPgS
minus the amount bound in its presence. For each construct, an aliquot
of the eluate from the Bio-Spin P-6 columns was chromatographed on
SDS-polyacrylamide gels and quantified by phosphorimage analysis to
determine the amount of radioactivity specifically incorporated into the
at band. These values were used to correct for differences in expression
of the various in vitro translated at subunits in the rhodopsin binding
assay. Under these conditions, approximately 15% of the added wild-
type at binds to ROS membranes.
Trypsin Resistance Assay—This assay was used to measure GTPgS
binding to the G protein a subunits. Approximately 30,000 cpm (0.012
pmol) of the in vitro translation reaction were diluted into 25 ml of
buffer B (50 mM Tris-HCl, pH 7.5, 6 mM MgCl2, 1 mM EDTA, 1 mM
dithiothreitol) and incubated for 2 h at 30 °C with 100 mM GTPgS. The
trypsin resistance assay was initiated by incubation with 0.3–0.6 mg of
trypsin (sequencing grade modified trypsin, Promega) for 30 min at
30 °C. The reaction was terminated by the addition of SDS-Laemmli
sample buffer (25). The samples were boiled and chromatographed on
10% SDS-polyacrylamide gels. The gels were treated with Amplify and
analyzed as described above. For each construct, an aliquot of the in
vitro translation product was chromatographed on SDS-polyacrylamide
gels and quantified by phosphorimage analysis to correct for differences
in expression levels as described above.
Sucrose Density Gradient Sedimentation—In vitro translated prod-
ucts of at and at mutants (80,000 cpm, 0.032 pmol) were mixed with 100
ml of buffer A and overlaid on a 5–20% linear sucrose gradient in buffer
A (16). After centrifugation at 4 °C for 16 h at 55,000 rpm in an SW55Ti
rotor, the gradients were fractionated into 250-ml aliquots per tube and
chromatographed on SDS-polyacrylamide gels followed by phosphorim-
age analysis. The two peak fractions from each sample were selected
and reapplied to SDS-polyacrylamide gels, followed again by phosphor-
image analysis for estimation of the sizes of the different peaks.
RESULTS
Fig. 1 shows the COOH-terminal 11 amino acids of at and 5
other members of the G protein a subunit family. Two of these
amino acids, Leu-344 and Leu-349 in at, are conserved among
all G protein a subunits. A positively charged amino acid (Lys-
345 in at) and a hydrophobic amino acid at the COOH terminus
is conserved in most a subunits. Gly-348, previously shown in
at to be critical for the interaction of a synthetic peptide corre-
sponding to this sequence with rhodopsin (3), is preserved in ai
and ao but is replaced by other amino acids outside the ai/o/t
family.
A binding assay for measuring the interaction of at with
rhodopsin-containing membranes was developed using 35S-la-
beled, in vitro translated protein. This assay is based on the
formation of a stable complex between rhodopsin and Gt in the
absence of guanine nucleotide (26–28). Fig. 2A shows the bind-
ing of in vitro translated at and as to bovine ROS membranes.
The binding of at to rhodopsin in the light is approximately
twice the level of binding in the dark. The addition of GTPgS,
a nonhydrolyzable GTP analog, releases at from the mem-
branes, reflecting the promotion of guanine nucleotide ex-
change by rhodopsin in this system. In contrast, as, which does
not interact with rhodopsin, showed no significant increase in
binding in the light compared to samples kept in the dark and
was not released by incubation with GTPgS. The observed
GTPgS-dependent release of at from ROS membranes incu-
bated in the dark suggests that some of the rhodopsin in these
preparations is already bleached. For this reason, GTPgS-de-
pendent binding (the difference between the binding of at to
photolyzed rhodopsin in the presence and absence of GTPgS)
rather than light-dependent binding (the difference between at
binding to rhodopsin in the light and in the dark) was used in
all subsequent experiments as a measure of specific interaction
with rhodopsin. It has been established by several laboratories
that at requires the presence of bg to form a stable complex
with rhodopsin (29–31), suggesting that bg is present in our
assay system. Immunoblots (Fig. 2B) performed with subunit-
specific antibodies (32) confirmed the presence of low levels of
at, b, and g (data not shown) in these ROS preparations.
Therefore, the in vitro translated at and ROS membranes were
incubated together without further addition of bg to the rho-
dopsin binding assay.
The COOH-terminal seven amino acids of at were mutated
individually to alanines, expressed by in vitro translation, and
assayed for rhodopsin binding. Fig. 3A shows an autoradio-
gram of the rhodopsin binding assay. The results were quanti-
fied by phosphorimage analysis and are shown in Fig. 3B.
Mutants L344A and L349A demonstrated the most severe (96
and 93%, respectively) loss of binding. C347A, the site of ADP-
ribosylation by pertussis toxin (33), G348A, the site of a pro-
posed b turn in the COOH terminus (3), and F350A were
moderately affected, demonstrating a 32, 36, and 30% loss of
binding to rhodopsin, respectively. All of the alanine mutants
that bound to rhodopsin (K345A, D346A, C347A, G348A, and
F350A) were released by the addition of GTPgS, indicating that
they are able to undergo receptor-mediated guanine nucleotide
exchange.
FIG. 1. The COOH-terminal amino acid sequence of six repre-
sentative G protein a subunits. The numbers in parentheses corre-
spond to the amino acids of each a subunit displayed in the figure. The
boxes outline the two leucine residues conserved among all of the a
subunits. The underlined amino acids in at are those chosen for mu-
tagenesis in this study.
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The sensitivity of the two leucines to disruption by alanine
mutagenesis raised questions concerning the structural integ-
rity of these mutants. G protein-coupled receptors function as
ligand exchange enzymes, meaning that they promote the ex-
change of a ligand, in this case guanine nucleotide bound to the
G protein a subunit (34). Basal guanine nucleotide exchange
occurs in at at a slow but measurable rate that is enhanced
approximately 70-fold in the presence of photolyzed rhodopsin
(32). The loss of basal GTPgS binding in the at mutants would
suggest more extensive changes in the overall structure of the
subunit. The binding of guanine nucleotide can be measured by
examining the resistance of at to digestion by trypsin in the
presence of GTPgS (35–37). Fig. 4A demonstrates that in vitro
translated at is digested almost entirely by high concentrations
of trypsin in the absence of guanine nucleotide. In contrast, a
32-kDa band is protected from digestion in the presence of
GTPgS. A 23-kDa band observed in the trypsin-digested sam-
ples is due to protection by GDP present in the in vitro trans-
lation mixture (16, 37). The amount of the trypsin-resistant
32-kDa band increased to 40% of the total in vitro translated at
FIG. 2. The binding of at and as to ROS membranes. A, [
35S]me-
thionine-labeled, in vitro translated at and as were incubated with ROS
membranes in the dark or in the light, with or without GTPgS and
analyzed as described under “Experimental Procedures.” B, Western
blot analysis of ROS membranes. Urea-stripped ROS membranes were
immunoblotted with antibodies against at and bg antibodies and visu-
alized as described under “Experimental Procedures.”
FIG. 3. The binding of at COOH-terminal alanine mutants to
rhodopsin. A, mutations generated in the COOH terminus of at were
expressed by in vitro translation in the presence of [35S]methionine and
incubated with ROS membranes in the light, in the presence or absence
of GTPgS. The samples were visualized by SDS-PAGE and autoradiog-
raphy as described under “Experimental Procedures.” B, phosphorim-
age analysis of the results shown in A. The results represent the
binding of the at mutants to rhodopsin as a percent of the binding of
wild-type at. The bars represent the averages of at least three inde-
pendent experiments. The error bars represent S.E.
FIG. 4. Trypsin resistance of in vitro translated at as ameasure
of guanine nucleotide binding. A, concentration dependence of
GTPgS-dependent trypsin resistance. [35S]Methionine-labeled, in vitro
translated at was preincubated with or without 100 mM GTPgS for 2 h,
followed by the addition of the indicated concentrations of trypsin and
incubation for 30 min. The reaction was terminated by the addition of
Laemmli sample buffer (25) and analyzed by SDS-PAGE as described
under “Experimental Procedures.” In addition to the full-length 39-kDa
(wild-type at) band, other bands appear in the absence of trypsin and
GTPgS that represent translation initiation at methionines down-
stream from the primary initiation codon. A 38-kDa band, appearing at
lower concentrations of trypsin, is a partial digest of at, described
previously (37). The 32- and 23-kDa bands are GTPgS- and GDP-
protected fragments of at, respectively. Numbers on the left side of the
gel indicate approximate molecular weights of prestained molecular
markers (Bio-Rad). B, time course of GTPgS binding to at using the
trypsin resistance assay. [35S]Methionine-labeled at was incubated with
100 mM GTPgS for the indicated duration, followed by incubation with
0.5 mg of trypsin for 30 min. The samples were subjected to SDS-PAGE
followed by phosphorimage analysis. The results are presented as a
percent of trypsin-resistant 32-kDa band compared to undigested at.
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during 8 h of incubation with GTPgS (Fig. 4B). In contrast,
more than 80% of as and ai is protected after only a 2-h
incubation in GTPgS (data not shown), suggesting that these a
subunits undergo basal guanine nucleotide exchange at a much
higher rate than at in our assay mixture, which contains ap-
proximately 6 mM Mg21 ion.
The COOH-terminal alanine mutants were tested for their
ability to resist digestion by trypsin in the presence of GTPgS
(Fig. 5). C347A and F350A showed a partial decrease in trypsin
resistance of 56 and 41%, respectively. The most dramatically
affected mutants were L344A and L349A. Very little of the
protected 32-kDa band was detected in these samples. There-
fore, these mutants appear to be unable to bind GTPgS. Nei-
ther L344A nor L349A showed significant amounts of the 23-
kDa protected fragment, indicating that they may not bind
GDP. Incubation with very high concentrations (2 mM) of either
GTP or GDP also did not protect these mutants from trypsin
digestion, although both the 32- and the 23-kDa fragments
were apparent in samples of wild-type at (data not shown).
Therefore, these mutants are incapable of binding any form of
guanine nucleotide. These results demonstrate a parallel loss
of both rhodopsin binding and guanine nucleotide binding for
L344A and L349A.
To investigate in more detail the influence of mutation on the
properties of at, the seven COOH-terminal residues were re-
placed with different amino acids and assayed for both rhodop-
sin binding and trypsin resistance (Fig. 6). When isoleucine, a
hydrophobic amino acid, was introduced at Leu-344 and Leu-
349, the resulting proteins demonstrated trypsin resistance at
69 and 50% of wild-type levels, respectively, and rhodopsin
binding at 43 and 27% of wild-type levels, respectively, sug-
gesting that these sites are more critical for rhodopsin binding
than for guanine nucleotide binding. Interestingly, mutation to
phenylalanine at these positions resulted in significantly re-
duced activity in both assays, particularly for L344F, perhaps
due to steric hindrance caused by the larger size of this amino
acid. Rhodopsin binding and guanine nucleotide binding are
both abolished by the substitution of proline for Lys-345 or
Asp-346. These data suggest that fixing the angle of the COOH
terminus with a proline at residue 345 or 346 disrupts both
activities of the protein. In contrast, the introduction of a pro-
line at Gly-348 dramatically inhibited rhodopsin interaction
but caused only a 39% decrease in intrinsic guanine nucleotide
binding. Mutation of Gly-348 to asparagine (G348N) or leucine
(G348L) caused significant (53 and 57%, respectively) losses in
rhodopsin binding but only small (18 and 27%, respectively)
losses in guanine nucleotide binding. Mutation of Cys-347, also
conserved in the ai/o/t family, to alanine, caused a partial de-
crease in both rhodopsin binding (to 68%) and guanine nucle-
otide binding (to 44%). In contrast, both receptor binding and
guanine nucleotide binding were lost when this residue was
mutated to tyrosine, the amino acid found at the equivalent
position in both as and aq. The COOH-terminal residue, Phe-
350, is tolerant to substitutions, retaining activity when
changed to alanine (weakly hydrophobic) and glutamine (hy-
drophilic), and exhibiting significantly reduced activity (a 72
and a 65% loss in rhodopsin binding and trypsin resistance,
respectively) only when mutated to glutamic acid, a negatively
charged amino acid.
Additional point mutations and deletions at the amino and
COOH termini of at were compared for rhodopsin and guanine
nucleotide binding activities (Fig. 7). The double mutation
K345A/D346A, in which two charged residues are eliminated,
and a mutation equivalent to the ao sequence, D346G/F350Y,
bound guanine nucleotide and interacted with rhodopsin as
well as wild-type at. In contrast, the mutant D346E/C347Y/
G348N/F350V, which represents the COOH-terminal sequence
of aq, could not bind rhodopsin but bound guanine nucleotide
normally. Interestingly, removal of a single amino acid from
the COOH terminus (F350stop) was sufficient to destroy both
rhodopsin and guanine nucleotide binding, despite the toler-
ance of Phe-350 to point mutagenesis shown in Fig. 6. Exten-
sion of the COOH terminus by a single alanine (stop351A) also
caused a complete loss of both rhodopsin and guanine nucleo-
tide binding. Mutations at the amino terminus, such as G2A (in
which the myristoylation site is removed), and the deletions
delN6/A7M and delN10/H11M resulted in a loss of receptor
binding (data not shown) but no loss of guanine nucleotide
binding, suggesting that the loss of guanine nucleotide binding
and rhodopsin interaction simultaneously is specific to the
COOH terminus.
This parallel loss of rhodopsin and guanine nucleotide exhib-
ited by the COOH-terminal mutants could be due to denatur-
ation of the polypeptides. To investigate this possibility, the
wild-type protein and mutants L344A, G348A, and F350stop
were analyzed by sucrose density gradient sedimentation (Fig. 8).
The peak fractions of all of these proteins were at the same
position in the gradient. Similar amounts of G348A were re-
covered from the gradients compared to wild-type at. However,
FIG. 5. Trypsin resistance of at COOH-terminal alanine mu-
tants in the presence of GTPgS. A, in vitro translated [35S]-labeled
at mutants were incubated in the presence and absence of GTPgS and
subjected to trypsin digestion followed by SDS-PAGE and autoradiog-
raphy as described under “Experimental Procedures.” B, phosphorim-
age analysis of the results shown in A. The amount of 32-kDa band
(GTPgS bound fragment) was quantified by phosphorimage analysis.
For each mutant, the results represent the amount of 32-kDa trypsin-
resistant fragment as a percent of the amount of wild-type at 32-kDa
fragment after trypsin digestion. The numbers represent the average of
four to six samples. The error bars represent S.E.
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substantially less L344A and F350stop were recovered, despite
equal loading of these proteins on the gradients. No peaks were
observed at any other position on the sucrose gradients, which
could account for the lost radioactivity. A similar result was
observed by Denker et al. (16) with a 14-amino acid COOH-
terminal truncation of ao, which, when stripped of guanine
nucleotide, formed no discrete peaks on sucrose density gradi-
ents. These data imply that L344A and F350stop are less stable
than wild-type at and are likely to be denatured in our assays.
There have been no reports in the literature of such sensi-
tivity to mutagenesis in the COOH terminus of other G pro-
teins, raising the prospect that our observations are specific for
at. To test this possibility, the equivalent of the mutant
atL344A was also generated in as (L388A) and ai2 (L349A).
Neither asL388A nor ai2L349A demonstrated a severe decrease
in GTPgS-dependent trypsin resistance compared to their re-
spective wild-type proteins, indicating that these mutants are
better able to bind guanine nucleotide than the equivalent at
mutant (Figs. 9 and 10). Because ai is closely related in se-
quence to at and can be activated by rhodopsin (38), the ability
of aiL349A to bind rhodopsin was measured (Fig. 10). This
mutant showed only a modest decrease in rhodopsin binding
(35%) compared to wild-type ai. Therefore, the extreme sensi-
tivity of the at COOH terminus to mutagenesis does not appear
to be shared with other members of the G protein a subunit
family.
DISCUSSION
A number of laboratories have suggested that information
for receptor interaction resides in the COOH terminus of G
protein a subunits (1–3, 5–12). Using NMR, Dratz et al. (3)
described the structure of a synthetic peptide corresponding to
the COOH-terminal 11 amino acids of at (amino acids 340–350)
bound to rhodopsin. Gly-348 was shown to be essential to the
formation of a b turn, which was necessary for the binding of
the COOH-terminal peptide to rhodopsin. In these studies,
substitution of this glycine with leucine abolished the binding
of the synthetic peptide. In our experiments, replacement of
Gly-348 with alanine, leucine, or asparagine partially reduced
rhodopsin binding, whereas substitution with proline abolished
this interaction. All of these mutations had a less severe effect
on guanine nucleotide binding, suggesting that this residue is
critical for the interaction of at with rhodopsin. However, the
effect of mutation of Gly-348 on rhodopsin binding was less
severe than would be predicted from the synthetic peptide
studies described above. Perhaps other regions in the full-
length protein also interact with rhodopsin and partially com-
pensate for the loss of this COOH-terminal residue. For exam-
ple, residues 311–329 have been proposed to interact with
rhodopsin and to participate in receptor-catalyzed guanine nu-
FIG. 6.Rhodopsin binding and tryp-
sin resistance for additional at COOH-
terminal point mutants. The seven
COOH-terminal amino acid residues of at
were subjected to further mutagenesis.
These mutants were expressed by in vitro
translation, radiolabeled with [35S]methi-
onine, and used for rhodopsin binding and
trypsin resistance assays as described un-
der “Experimental Procedures” and the
legends to Figs. 3 and 5. *, the error bars
represent the ranges of two samples for
both assays. In all other samples, the er-
ror bars represent S.E. determined from
at least three samples. For comparison,
the results shown in Figs. 3 and 5 are
included in this figure.
FIG. 7. Rhodopsin binding and trypsin resistance of amino-
and COOH-terminal mutants of at. A, amino- and COOH-terminal
mutants of at were assayed for their ability to bind rhodopsin and for
trypsin resistance in the presence of GTPgS, as described in the legends
to Figs. 3 and 5 and under “Experimental Procedures.” Group I, rho-
dopsin binding was determined from duplicate samples; group II, rho-
dopsin binding was determined from a single sample. *, trypsin resist-
ance was determined from four samples for D346E/C347Y/G348N/
F350V. All error bars represent the range of duplicate samples except
D346E/C347Y/G348N/F350V, which is shown as S.E. The groups I, II,
and III are described in Fig. 7B. B, sequences of the mutations used for
rhodopsin binding and trypsin resistance assays shown in A.
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cleotide exchange (2, 39). Dratz et al. (3) also reported that the
b turn in the rhodopsin-bound conformation of the peptide
disappeared when rhodopsin was converted to metarhodopsin
II by exposure to light. From this result, a requirement for
flexibility at Gly-348 for binding to light-exposed rhodopsin
may be inferred, which is consistent with our observation that
proline is more effective at disrupting rhodopsin binding than
other amino acids at this position. Proline substitutions at the
neighboring residues, Lys-345 and Asp-346, abolished both
rhodopsin binding and guanine nucleotide binding. Therefore,
these two residues are more critical for guanine nucleotide
binding than is Gly-348.
Conklin et al. (11) reported that replacement of the last three
amino acids of aq with the sequence found in ai (amino acids
NLV to GLF) was sufficient to allow the activation of this
chimera by the D2 dopamine receptor, a Gi-coupled receptor.
Therefore, not only is the COOH terminus responsible for bind-
ing to receptor, it also contains information that determines the
selectivity between G proteins and their receptors. In our ex-
periments, C347Y, a substitution in at with the aq amino acid,
exhibited a dramatic loss of both rhodopsin and guanine nucle-
otide binding. Substitution of this amino acid along with other
amino acids corresponding to aq sequence (D346E/C347Y/
G348N/F350V) resulted in a rescue of guanine nucleotide bind-
ing but no restoration of rhodopsin binding. These data indi-
cate that the tertiary structure of the surrounding domains
may be drastically affected by a single mutation but is pre-
served when the sequence of another a subunit representing a
complete structural motif is introduced. Understanding the
role of C347Y and its surrounding structural motif in receptor
interaction will require further study.
The removal or addition of a single amino acid at Phe-350 but
not its substitution resulted in a loss of both receptor coupling
and guanine nucleotide binding, suggesting that the length of
the COOH terminus is critical for the function of at. A dramatic
loss of both guanine nucleotide binding and rhodopsin binding
was observed for the COOH-terminal mutants L344A and
L349A as well. Mutations in Lys-345 and Asp-346 (to proline),
Cys-347 (to tyrosine), and Phe-350 (to glutamic acid) also ex-
hibited a parallel loss, either partial or complete, of both rho-
dopsin and guanine nucleotide binding. In contrast, the amino-
terminal mutants (G2A, delN6/A7M, and delN10/H11M)
showed only a loss of rhodopsin binding. This unexpected sen-
sitivity of the COOH terminus for changes in both activities
was shown to be specific for at. For example, mutations equiv-
alent to L344A in as (L388A) and ai (L349A) do not exhibit a
large decrease in guanine nucleotide binding. Moreover,
aiL349A showed only a small decrease in rhodopsin binding
compared to the wild-type protein. In ao, removal of 5, 10, or
even 14 amino acids from the COOH terminus was reported to
have no effect on the binding of GTPgS, although the 14-amino
acid deletion mutant lost affinity for GDP (16). Therefore, as,
ai, and ao are clearly less susceptible than at to alteration of the
COOH terminus. The reduced recovery of L344A and F350stop
from sucrose density gradients suggest that the at COOH-
terminal mutants are unstable and susceptible to denatur-
ation, which may account for the loss of both rhodopsin and
guanine nucleotide binding.
FIG. 8. Sedimentation profiles of at
and at mutants on sucrose density
gradients. 80,000 cpm of in vitro trans-
lated products were overlaid on 5–20%
linear sucrose gradients and centrifuged
for 16 h at 55,000 rpm in an SW55Ti rotor
at 4 °C. After centrifugation, the gradi-
ents were fractionated into 250-ml ali-
quots per tube and chromatographed by
SDS-PAGE followed by phosphorimage
analysis as described under “Experimen-
tal Procedures.” The data are representa-
tive of three independent experiments.
FIG. 9. Trypsin resistance of as and ai mutants. Mutants at the
equivalent position with atL344A in as (L388A) and ai (L349A) were
assayed for resistance to trypsin in the presence of GTPgS. The
asL388A and aiL349A mutants produced trypsin-resistant fragments of
36 and 37 kDa, respectively. Several bands that appear below the major
in vitro translation product in the lanes without trypsin are peptides
translated from ATG sites downstream from the ATG initiation site.
FIG. 10. Rhodopsin binding and trypsin resistance in as and ai
mutants. Rhodopsin binding and trypsin resistance assays were per-
formed for as L388A and ai L349A, as described under “Experimental
Procedures.” Error bars represent the range of duplicate samples.
Shaded bars, rhodopsin binding; lined bars, trypsin resistance.
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The at subunit is known to possess several structural and
functional properties that are distinct from other closely re-
lated G protein a subunits. Unlike ai or ao (40, 41), the rate of
receptor-independent guanine nucleotide exchange in at is not
affected by magnesium ion (32). X-ray crystallographic analysis
also shows differences between at and ai at the sites of contact
with guanine nucleotide (42). Other differences are apparent in
the amino terminus. When counted from the common b1
strand, at has the shortest amino terminus and is not modified
by palmitic acid like other a subunits of this family (ai, ao). In
addition, at is heterogeneously acylated with myristate or one
of three other fatty acids (43, 44), whereas ai is acylated only
with myristic acid. This heterogeneous modification is so far
unique to retinal photoreceptor cells (45). Therefore, it is pre-
sumed that in vitro translated at (synthesized in a rabbit re-
ticulocyte lysate) is predominantly myristoylated and similar
in modification to ai, ruling out differences in myristoylation, at
least, as an explanation for our observations. Many laborato-
ries using a variety of techniques have concluded that the
amino and COOH termini are closely associated, allowing for
coordinate regulation of bg and receptor binding, as well as
control of guanine nucleotide binding (37, 46–48). At present,
the possibility that the unique properties of the at COOH
terminus are due to association with a unique amino terminus
is speculative because the extreme amino termini of at (amino
acids 1–26) and ai (amino acids 1–32) have not been resolved by
x-ray crystallography. However, the orientation of the adjacent
regions is consistent with their close approximation (39, 42, 49,
50). Future studies in which the amino terminus from ai is
substituted for that of at in the L344A, L349A, and F350stop
mutants, for example, will help to clarify the relationship be-
tween these two domains and their role in rhodopsin and gua-
nine nucleotide binding.
The present report describes the use of mutagenesis to un-
derstand the role of the COOH-terminal amino acids of at in
rhodopsin binding. Of the alanine mutants, L344A and L349A
showed the most dramatic decrease in rhodopsin binding and
guanine nucleotide binding. Alternative substitutions suggest
a preference for hydrophobic amino acids at these positions.
Mutations in Gly-348 demonstrated that this residue is more
important for rhodopsin binding than for guanine nucleotide
binding and that flexibility at this position is critical for the
interaction of the COOH terminus with rhodopsin. A compar-
ison between C347Y and a mutant substituted with the aq
sequence (including C347Y) implies that structural motifs exist
in the COOH terminus that maintain the structure of the a
subunit and are necessary for selective interaction with G-
protein-coupled receptors. Mutations at nearly every position
in the COOH terminus of at but not in the amino terminus
caused an unexpected parallel loss of rhodopsin binding and
guanine nucleotide binding. Since mutations equivalent to
atL344A in as and ai did not exhibit a dramatic decrease in
these activities, we conclude that the at COOH terminus is
uniquely susceptible to amino acid alterations compared to
other closely related G-protein a subunits, perhaps reflecting
distinct biochemical properties necessary for function of this
rod cell-specific G protein.
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